공지 : 도쿄증권거래소 JASDAQ 스탠다드 시장 신규 상장 관련 안내

Global Information
회사소개 | 문의 | 비교리스트

티로신 프로테인 키나아제 수용체 UFO : 파이프라인 리뷰

Tyrosine Protein Kinase Receptor UFO - Pipeline Review, H2 2019

리서치사 Global Markets Direct
발행일 2019년 12월 상품 코드 367823
페이지 정보 영문 185 Pages
가격
US $ 3,500 ₩ 4,009,000 PDF (Single user license) help
1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 7,000 ₩ 8,018,000 PDF (Site license) help
동일 사업장 내 모든 분들이 공유하여 사용할 수 있습니다. 이용 인원수에 제한은 없습니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 2부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 10,500 ₩ 12,027,000 PDF (Global license) help
동일 기업의 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없으며, 해외 사업장 및 100% 자회사는 동일 기업으로 간주됩니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 10부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.


티로신 프로테인 키나아제 수용체 UFO : 파이프라인 리뷰 Tyrosine Protein Kinase Receptor UFO - Pipeline Review, H2 2019
발행일 : 2019년 12월 페이지 정보 : 영문 185 Pages

본 상품은 영문 자료로 한글과 영문목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

티로신 프로테인 키나아제 수용체 UFO를 표적으로 한 치료제 개발 파이프라인의 현황과 최신 업데이트에 의한 각 개발 단계 비교 분석, 기업 및 연구기관에 의해 개발중인 치료제, 치료제 평가, 후기 단계 및 중지된 프로젝트에 관한 정보 등을 최신 뉴스 및 발표와 함께 정리하여 전해드립니다.

서론

  • 조사 범위

티로신 프로테인 키나아제 수용체 UFO 개요

치료제 개발

  • 개발중인 제품 : 개발 단계별
  • 개발중인 제품 : 치료 영역별
  • 개발중인 제품 : 증상별

파이프라인 제품 개요

  • 후기 단계 제품
  • 초기 단계 제품

기업에서 개발중인 제품

대학/기관에서 개발중인 제품

치료제 평가

  • 단일요법/병용 치료제의 경우
  • 작용기서별
  • 투여 경로별
  • 분자 유형별

치료제 개발에 참여하고 있는 기업

  • Astellas Pharma Inc.
  • BerGenBio AS
  • Betta Pharmaceuticals Co. Ltd.
  • Chugai Pharmaceutical Co., Ltd.
  • Exelixis, Inc.
  • HEC Pharm Co., Ltd.
  • Ignyta, Inc.
  • Les Laboratoires Servier SAS
  • Mirati Therapeutics Inc.
  • NeoPharm Co., Ltd.
  • Oribase Pharma
  • SignalChem Lifesciences Corp
  • Tolero Pharmaceuticals, Inc.

약제 개요

휴지중인 프로젝트

개발이 중지된 제품

주요 뉴스 및 프레스 릴리스

부록

도표

KSA 16.09.12

List of Tables

  • Number of Products under Development by Stage of Development, H2 2019
  • Number of Products under Development by Therapy Areas, H2 2019
  • Number of Products under Development by Indications, H2 2019
  • Number of Products under Development by Indications, H2 2019 (Contd..1), H2 2019
  • Number of Products under Development by Indications, H2 2019 (Contd..2), H2 2019
  • Number of Products under Development by Indications, H2 2019 (Contd..3), H2 2019
  • Number of Products under Development by Indications, H2 2019 (Contd..4), H2 2019
  • Number of Products under Development by Companies, H2 2019
  • Number of Products under Development by Companies, H2 2019 (Contd..1)
  • Products under Development by Companies, H2 2019
  • Products under Development by Companies, H2 2019 (Contd..1), H2 2019
  • Products under Development by Companies, H2 2019 (Contd..2), H2 2019
  • Products under Development by Companies, H2 2019 (Contd..3), H2 2019
  • Products under Development by Companies, H2 2019 (Contd..4), H2 2019
  • Products under Development by Companies, H2 2019 (Contd..5), H2 2019
  • Products under Development by Companies, H2 2019 (Contd..6), H2 2019
  • Products under Development by Companies, H2 2019 (Contd..7), H2 2019
  • Products under Development by Companies, H2 2019 (Contd..8), H2 2019
  • Products under Development by Companies, H2 2019 (Contd..9), H2 2019
  • Products under Development by Companies, H2 2019 (Contd..10), H2 2019
  • Number of Products under Investigation by Universities/Institutes, H2 2019
  • Products under Investigation by Universities/Institutes, H2 2019
  • Number of Products by Stage and Mechanism of Actions, H2 2019
  • Number of Products by Stage and Route of Administration, H2 2019
  • Number of Products by Stage and Molecule Type, H2 2019
  • Pipeline by Arcus Biosciences Inc, H2 2019
  • Pipeline by Astellas Pharma Inc, H2 2019
  • Pipeline by BerGenBio ASA, H2 2019
  • Pipeline by Betta Pharmaceuticals Co Ltd, H2 2019
  • Pipeline by Celldex Therapeutics Inc, H2 2019
  • Pipeline by Daiichi Sankyo Co Ltd, H2 2019
  • Pipeline by Eli Lilly and Co, H2 2019
  • Pipeline by Exelixis Inc, H2 2019
  • Pipeline by F. Hoffmann-La Roche Ltd, H2 2019
  • Pipeline by F1 Oncology Inc, H2 2019
  • Pipeline by Genosco Inc, H2 2019
  • Pipeline by HEC Pharm Co Ltd, H2 2019
  • Pipeline by Hope Biosciences Inc, H2 2019
  • Pipeline by Incyte Corp, H2 2019
  • Pipeline by Konruns Pharmaceutical Co Ltd, H2 2019
  • Pipeline by Mirati Therapeutics Inc, H2 2019
  • Pipeline by Novithera SAS, H2 2019
  • Pipeline by Ono Pharmaceutical Co Ltd, H2 2019
  • Pipeline by Oribase Pharma, H2 2019
  • Pipeline by Qurient Co Ltd, H2 2019
  • Pipeline by Rigel Pharmaceuticals Inc, H2 2019
  • Pipeline by SignalChem Lifesciences Corp, H2 2019
  • Pipeline by Symphogen A/S, H2 2019
  • Pipeline by Takeda Pharmaceutical Co Ltd, H2 2019
  • Pipeline by TamRx LLC, H2 2019
  • Pipeline by Tolero Pharmaceuticals Inc, H2 2019
  • Pipeline by Vichem Chemie Research Ltd, H2 2019
  • Dormant Products, H2 2019
  • Dormant Products, H2 2019 (Contd..1), H2 2019
  • Dormant Products, H2 2019 (Contd..2), H2 2019

List of Figures

  • Number of Products under Development by Stage of Development, H2 2019
  • Number of Products under Development by Therapy Areas, H2 2019
  • Number of Products under Development by Top 10 Indications, H2 2019
  • Number of Products by Stage and Mechanism of Actions, H2 2019
  • Number of Products by Routes of Administration, H2 2019
  • Number of Products by Stage and Routes of Administration, H2 2019
  • Number of Products by Molecule Types, H2 2019
  • Number of Products by Stage and Molecule Types, H2 2019

Summary

Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) - Tyrosine-protein kinase receptor UFO is an enzyme encoded by the AXL gene. It plays a role in various processes such as endothelial cell survival during acidification by preventing apoptosis, optimal cytokine signaling during human natural killer cell development, hepatic regeneration, gonadotropin-releasing hormone neuron survival and migration, platelet activation, or regulation of thrombotic responses. It plays also an important role in inhibition of Toll-like receptors (TLRs)-mediated innate immune response.

Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) pipeline Target constitutes close to 32 molecules. Out of which approximately 30 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 3, 5, 7, 10 and 4 respectively. Similarly, the universities portfolio in Preclinical stages comprises 2 molecules, respectively. Report covers products from therapy areas Oncology, Cardiovascular, Gastrointestinal, Non Malignant Disorders and Respiratory which include indications Non-Small Cell Lung Cancer, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Solid Tumor, Gastric Cancer, Breast Cancer, Melanoma, Metastatic Colorectal Cancer, Ovarian Cancer, Metastatic Melanoma, Triple-Negative Breast Cancer (TNBC), Adenocarcinoma Of The Gastroesophageal Junction, Bladder Cancer, Cervical Cancer, Chronic Lymphocytic Leukemia (CLL), Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), Colorectal Cancer, Endometrial Cancer, Epithelial Ovarian Cancer, Esophageal Cancer, Ewing Sarcoma, Gastroesophageal (GE) Junction Carcinomas, Head And Neck Cancer, Head And Neck Cancer Squamous Cell Carcinoma, Hepatocellular Carcinoma, Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Metastatic Renal Cell Carcinoma, Metastatic Uveal Melanoma, Myelodysplastic Syndrome, Osteosarcoma, Pancreatic Cancer, Renal Cell Carcinoma, Rhabdomyosarcoma, Soft Tissue Sarcoma, Thyroid Cancer, Wilms' Tumor (Nephroblastoma), Adenocarcinoma, Adrenocortical Carcinoma (Adrenal Cortex Cancer), Bile Duct Cancer (Cholangiocarcinoma), Bone Metastasis, Carcinoid Tumor, Colon Cancer, Fallopian Tube Cancer, Follicular Thyroid Cancer, Gallbladder Cancer, Gastrointestinal Stromal Tumor (GIST), Glioblastoma Multiforme (GBM), High-Grade Glioma, Idiopathic Pulmonary Fibrosis, Kidney Cancer (Renal Cell Cancer), Leiomyosarcoma, Liposarcoma, Liver Cancer, Lung Adenocarcinoma, Malignant Mesothelioma, Mantle Cell Lymphoma, Merkel Cell Carcinoma, Metastatic Adenocarcinoma of The Pancreas, Metastatic Biliary Tract Cancer, Metastatic Breast Cancer, Metastatic Hepatocellular Carcinoma (HCC), Metastatic Ovarian Cancer, Metastatic Transitional (Urothelial) Tract Cancer, Neuroendocrine Gastroenteropancreatic Tumors (GEP-NET), Neuroendocrine Tumors, Non-Alcoholic Steatohepatitis (NASH), Non-Hodgkin Lymphoma, Non-Rhabdomyosarcoma, Non-Small Cell Lung Carcinoma, Oral Cavity (Mouth) Cancer, Osteolytic Bone Metastasis, Pancreatic Ductal Adenocarcinoma, Papillary Renal Cell Carcinoma, Papillary Thyroid Cancer, Paraganglioma (Glomus Jugulare Tumor), Penile Cancer, Peritoneal Cancer, Pheochromocytoma, Plexiform Neurofibroma, Prostate Cancer, Rectal Cancer, Recurrent Head And Neck Cancer Squamous Cell Carcinoma, Refractory Multiple Myeloma, Relapsed Multiple Myeloma, Salivary Gland Cancer, Squamous Cell Carcinoma, T-Cell Acute Lymphocytic Leukemia (T-Cell Acute Lymphoblastic Leukaemia), Thrombosis, Thymoma (Thymic Epithelial Tumor), Transitional Cell Cancer (Urothelial Cell Cancer), Transitional Cell Carcinoma (Urothelial Cell Carcinoma), Ureter Cancer, Urethral Cancer and Uterine Cancer.

The latest report Tyrosine Protein Kinase Receptor UFO - Pipeline Review, H2 2019, outlays comprehensive information on the Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1)
  • The report reviews Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) targeted therapeutics

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

List of Tables

List of Figures

  • Introduction
  • Global Markets Direct Report Coverage
  • Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) - Overview
  • Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) - Therapeutics Development
  • Products under Development by Stage of Development
  • Products under Development by Therapy Area
  • Products under Development by Indication
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
  • Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) - Therapeutics Assessment
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) - Companies Involved in Therapeutics Development
  • Arcus Biosciences Inc
  • Astellas Pharma Inc
  • BerGenBio ASA
  • Betta Pharmaceuticals Co Ltd
  • Celldex Therapeutics Inc
  • Daiichi Sankyo Co Ltd
  • Eli Lilly and Co
  • Exelixis Inc
  • F. Hoffmann-La Roche Ltd
  • F1 Oncology Inc
  • Genosco Inc
  • HEC Pharm Co Ltd
  • Hope Biosciences Inc
  • Incyte Corp
  • Konruns Pharmaceutical Co Ltd
  • Mirati Therapeutics Inc
  • Novithera SAS
  • Ono Pharmaceutical Co Ltd
  • Oribase Pharma
  • Qurient Co Ltd
  • Rigel Pharmaceuticals Inc
  • SignalChem Lifesciences Corp
  • Symphogen A/S
  • Takeda Pharmaceutical Co Ltd
  • TamRx LLC
  • Tolero Pharmaceuticals Inc
  • Vichem Chemie Research Ltd
  • Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) - Drug Profiles
  • Antibodies to Inhibit AXL, MERTK and TYRO3 for Oncology, Inflammation, Autoimmune Diseases and Infectious Disease - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • bemcentinib - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • BGB-149 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • BPI-9016 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Cabometyx - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) - Dormant Products
  • Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) - Product Development Milestones
  • Featured News & Press Releases
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer
Back to Top
전화 문의
F A Q